Cornish businessman scoops Topra award

Jonathan Trethowan wins Inspiration category

Jonathan Trethowan, director of regulatory affairs company Trac Services, based in Camborne, Cornwall, UK, has taken top honours in the Inspiration category at the Topra Symposium (the organisation representing regulatory affairs professionals).

A panel of five judges awarded Trethowan the honour at the awards, which recognise excellence within the industry, after he was nominated by Trac’s regulatory affairs executive, Lisa Pascoe.

Trethowan set up the company with his wife Sarah in 2001 and has seen it grow to work with UK and European pharmaceutical companies, ensuring that they are in compliance with the latest regulations concerned with the manufacture and marketing of medicines.

‘I am absolutely delighted to have won the Inspiration Award – it is a fantastic honour and to be honest I was thrilled just to be nominated,’ said Trethowan.

Pascoe added: ‘Over the past five years Jonathan has developed an excellent in-house training programme that has helped coach and support myself and six other graduates to become experienced regulatory professionals in our own right.

‘In addition, he also participates in a TOPRA working party that is identifying future approaches to professional development; I think his involvement at TRAC and within the industry as a whole shows his passion and commitment.’

You may also like

Regulatory

Amcor’s Winterbourne site achieves ISO 13485 certification, strengthening its position and capabilities in healthcare

ISO 13485:2016 is an internationally recognised quality management standard specifically for medical devices.
Regulatory

Roche wins CE mark for first blood-based immunoassay to identify ApoE4 Alzheimer's risk variant

Roche's Elecsys ApoE4 test has received CE mark approval as the first in-vitro diagnostic immunoassay to detect the ApoE4 genetic variant from a simple blood sample, potentially eliminating the need for confirmatory DNA testing in Alzheimer's patients who do not carry the variant
Regulatory

Orphan drug sales to exceed $400bn by 2032, Evaluate report finds

Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
Regulatory

Shilpa Biologicals and mAbTree secure FDA Orphan Drug Designation for rare blood cancer biologic

The FDA has granted Orphan Drug Designation to the pair's investigational monoclonal antibody for Essential Thrombocythemia and Polycythemia Vera, two rare chronic blood cancers with significant unmet treatment need
Media

CBA releases statement welcoming government's decision to incude biocides in post-Brexit negotiations

Biocides have now been officially included in the scope of negotiations, which the association has called an "important and practical step towards cutting red tape and restoring clarity for businesses," though the "reality is that much more still needs to be done"
Manufacturing

Lonza and Genetix extend commercial manufacturing agreement for ZYNTEGLO™

Expanded collaboration will support growing demand for FDA-approved gene therapy for beta-thalassemia
Regulatory

Orbia Fluor & Energy Materials registers US DMF file for low-GWP propellant

The fluor-based product manufacturer announced the creation of a US Type IV Drug Master File (DMF) for the low-GWP excipient Zephex 152a, with pharma companies now able to reference the data package for faster, lower-risk FDA reviews for pMDIs
Subscribe now